And SEKISUI Diagnostics, LLC (SEKISUI), a global manufacturer of innovative diagnostic tests, reagents, diagnostic systems, and raw materials, announce that Microbix external third-party quality assessment products will be used to support SEKISUI’s U.S. commercialization of the molecular point-of-care assay for diagnosis of COVID/Flu A/Flu B using the Metrix® platform from Aptitude Medical Systems, Inc. Microbix Biosystems Inc. shares T.MBX are trading unchanged at $0.25.
Stocks in play: Microbix Biosystems Inc.
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)
